Secondary Logo

Journal Logo

Most Popular Articles

DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy

Bernier, Cynthia; Soliman, Ahmed; Gravel, Michel; More

Anti-Cancer Drugs. 29(8):774-785, September 2018.

Preclinical testing of 5-amino-1-((1R,2S,3S,4R)-2,3-dihydroxy-4-methylcyclopentyl)-1H-imidazole-4-carboxamide: a potent protein kinase C-ι inhibitor as a potential prostate carcinoma therapeutic

Apostolatos, André H.; Apostolatos, Christopher A.; Ratnayake, Wishrawana S.; More

Anti-Cancer Drugs. 30(1):65-71, January 2019.

Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer

Durairaj, Chandrasekar; Ruiz-Garcia, Ana; Gauthier, Eric R.; More

Anti-Cancer Drugs. 29(3):271-280, March 2018.

Venous thromboembolic events in patients with lung cancer treated with cisplatin-based versus carboplatin/nedaplatin-based chemotherapy

Mitani, Akihisa; Jo, Taisuke; Yasunaga, Hideo; More

Anti-Cancer Drugs. 29(6):560-564, July 2018.

Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models

Capasso, Anna; Pitts, Todd M.; Klauck, Peter J.; More

Anti-Cancer Drugs. 29(9):827-838, October 2018.

A case of heavily pretreated metastatic cardiac angiosarcoma treated successfully using eribulin

Inagaki, Chiaki; Shimoi, Tatsunori; Okuma, Hitomi; More

Anti-Cancer Drugs. 29(1):97-101, January 2018.

Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer

Leonard, Shannon C.; Lee, Helen; Gaddy, Daniel F.; More

Anti-Cancer Drugs. 28(10):1086-1096, November 2017.

Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: a multicenter, randomized, crossover phase 3 study

Shi, Yuan-Kai; Chen, Qiang; Zhu, Yun-Zhong; More

Anti-Cancer Drugs. 24(6):641-647, July 2013.

Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer

Romero, Ignacio; Mallol, Pedro; Santaballa, Ana; More

Anti-Cancer Drugs. 30(6):628-635, July 2019.

Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands

Franken, Margreet G.; Leeneman, Brenda; Jochems, Anouk; More

Anti-Cancer Drugs. 29(6):579-588, July 2018.

Extravasation accidents with liposomal/liposomal pegylated anthracyclines treated with dexrazoxane: an overview and outcomes

Caballero Romero, Álvaro; Delgado Ureña, María Teresa; Salmerón García, Antonio; More

Anti-Cancer Drugs. 29(9):821-826, October 2018.

The role of HIPEC in the treatment of peritoneal carcinomatosis from gastric cancer: between lights and shadows

Di Vita, Maria; Cappellani, Alessandro; Piccolo, Gaetano; More

Anti-Cancer Drugs. 26(2):123-138, February 2015.

Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands

Jochems, Anouk; Leeneman, Brenda; Franken, Margreet G.; More

Anti-Cancer Drugs. 29(6):572-578, July 2018.

Determination of the maximal tumor:normal bladder ratio after i.p. or bladder administration of 5-aminolevulinic acid in Fischer 344 rats by fluorescence spectroscopy in situ

Bisson, Jean-François; Christophe, Marianne; Padilla-Ybarra, Juan-José; More

Anti-Cancer Drugs. 13(8):851-857, September 2002.

Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol®) and carboplatin in non-small cell lung cancer patients

Meerum Terwogt, Jetske M; van Tellingen, Olaf; Nannan Panday, Vinodh R; More

Anti-Cancer Drugs. 11(9):687-694, October 2000.